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Abstract: 
The MIC of cefepime determined with the MicroScan WalkAway 
system was >=2 times higher than that of ceftazidime for 105 
clinical isolates of Pseudomonas aeruginosa. This phenotype was 
confirmed by reference microdilution in 68 (64.8%) isolates, 
corresponding to 48 different rep-PCR patterns. The PSE-1 b-
lactamase was identified in only 13.2% isolates, while oxacillinases 
were not identified in any of the 68 isolates. The level of expression 
of  mexB, mexD and mexY  was determined by real time RT-PCR in 
8 clinical isolates representative of the different clones and patterns 
of  susceptibility to cefepime and ceftazidime and in strain PAO1. All 
clinical strains overexpressed the mexY gene (18.3 to 152.7-fold in 
comparison with PAO1), although there was not a linear 
relationship between MIC of cefepime and level of mexY expression. 
Five of these strains contained mutations in the regulatory gene 
mexZ. mexD and mexB were also overexpressed in 3 and 2 
isolates, respectively. Different mutations were observed in the 
regulatory genes nalD, mexR, nfxB and nalC. In conclusion, we 
have documented in our institution a polyclonal spread of P. 
aeruginosa with higher MICs of cefepime than to ceftazidime, 
related to overexpression of MexXY-OprM, coincident in some 
isolates with the production of PSE-1, MexCD-OprJ or MexAB-OprM. 
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INTRODUCTION 
MICs of cefepime against wild-type clinical isolates of Pseudomonas 
aeruginosa, are usually similar to those of ceftazidime [1]. However, strains 
intermediate or resistant to cefepime and susceptible to ceftazidime have been 
described [2-7]. This phenotype has been related to hyperproduction of the 
efflux system MexXY-OprM [2, 5-7] and/or  the production of OXA-31 [3], OXA-
35 [4] or PSE-1 [2, 7]. Although the MexCD-OprJ system does not contribute to 
the basal natural resistance of P. aeruginosa [8], when it is overexpressed it 
causes increased resistance to cefepime and other compounds 
(fluoroquinolones, macrolides,...) [9]. However, MexCD-OprJ  overexpression is 
uncommon among clinical isolates of P. aeruginosa, with the notable exception 
of isolates from cystic fibrosis patients. In a previous study, none of 38 isolates 
more resistant to cefepime than to cefazidime overexpressed the MexCD-OprJ 
[2]. Also, in a collection of bacteremic isolates, MexAB-OprM and MexXY-OprM 
were overexpressed in 11% and 36% of the isolates, respectively, while 
MexCD-OprJ overexpression was not detected in any isolate [10]. Similarly, 
only 4 out of 110 clinical isolates with decreased susceptibility to ciprofloxacin 
hyperproduced MexCD-OprJ, and although these 4 isolates were less 
susceptible to cefepime than to ceftazidime, it was not possible to demonstrate 
the direct involvement of this efflux system in the decreased activity of cefepime 
[11].  
On the other hand, susceptibility testing of P. aeruginosa to cefepime with 
several automatic systems has caused either major errors (false resistance) or 
minor errors (resulting from categorizing some isolates as intermediate to 
cefepime when they actually were susceptible to this compound) [12-17].  
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In our center, using the MicroScan WalkAway system (Dade Behring, 
Sacramento, CA), we have obtained during the last years clinical isolates of P. 
aeruginosa presenting lower susceptibility to cefepime than to ceftazidime. The 
objectives of this study were to confirm this phenotype using a standardized 
susceptibility testing assay and to describe the molecular mechanisms involved. 
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MATERIAL AND METHODS. 
Bacteria. One hundred and five consecutive clinical isolates of P. aeruginosa 
isolated in the period September 2004 to June 2005 for which the MIC of 
cefepime was >=2 times higher than that of ceftazidime were collected from  99 
patients (64 males and 35 females). During the study period, 1652 isolates of P. 
aeruginosa, cultured from 780 patients were obtained in our centre; the 105 
isolates we initially selected represent a 6.4% of all isolates, and the 99 patients 
correspond to 12.7% of all patients from whom P. aeruginosa was isolated. The 
organisms were cultured from wound exudates (n=44), respiratory samples 
(n=25), urines (n= 21), blood cultures (n=3 ) or others (n=12, including lung 
biopsy, semen and sterile fluids).  
Identification and susceptibility testing of the bacteria were performed with the 
MicroScan Walkaway 96 system, using Combo Neg 1S panels.  Isolates were 
maintained at –80ºC in tryptic soy broth with 10% glycerol. Organisms were 
plated out twice on Mueller-Hinton agar plates (Difco) before additional studies 
were performed. 
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Susceptibility testing. MICs of both cefepime (Bristol Myers Squibb, Madrid, 
España) and ceftazidime (Sigma, Madrid, España) against the indicated 105 
isolates were determined by microdilution, according to CLSI guidelines [18]. P. 
aeruginosa ATCC 27853 was included as a control. The microdilution assay 
was performed three times on three different days. The final MIC values 
considered in this study were those corresponding to the modal values for every 
isolate. Cefepime and ceftazidime susceptibilities of the 105 isolates were also 
determined by the disk-diffusion assay (CLSI guidelines), using 30 µg disks (BD 
BBL Sensi-DiscTM, USA). 
Molecular typing. Clonal relationship of the isolates was evaluated by REP-
PCR, using primers described by Vila et al. [19]. Amplicons were analysed by 
agarose gel electrophoresis. Two isolates were considered clonally unrelated 
when two or more different bands were observed.  Additionally, pulsed-field gel 
electrophoresis (PFGE) was performed in organisms presenting the same  
banding pattern or with only 1 band of difference. DNA agarose plugs were 
digested overnight with SpeI (Roche Diagnostics, Indianapolis, IN, USA) at 
37°C.  The restriction fragments were separated on 1% w/v agarose gels in 
0.5% TBE buffer in a CHEF-DR II electrophoresis system (Bio-Rad 
Laboratories, Richmond, CA, USA) for 26 h at 14ºC using a pulse ramping rate 
changing from 1 to 20 s at 6 V/cm. PFGE patterns were interpreted according to 
the criteria by Tenover et al. [20]. 
Analysis of resistance mechanisms. Detection of genes coding for 
oxacillinases of groups I, II y III, and penicillinase PSE-1 was performed by PCR 
in the 68 isolates for which the phenotype herein investigated was confirmed by 
reference microdilution (see below), using previously reported primers and 
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conditions [21, 22]. Amplicons (both strands) were sequenced using an external 
resource (Macrogen, Korea). 
The level of expression of mexB, mexD and mexY was determined by real time 
PCR (RT-PCR) in strain PAO1 and in 8 clinical isolates (representative of the 
different clones and patterns of susceptibility to cefepime and ceftazidime), 
including 5, 2 and 1 isolates for which the MIC of cefepime was higher than that 
of ceftazidime 2, 4 or 16 times, respectively (Table 1). Total RNA was extracted 
with the Rneasy Protect bacteria Mini Kit (QIAGEN, Hilden, Alemania), 
according to manufacturer's recommendations. DNA was removed with RNase-
Free DNase treatment and RNA preparations were tested for the lack of 
Pseudomonas aeruginosa DNA contamination by PCR with primers specific for 
the rpsL Pseudomonas gene. None of the RNA samples used in the study 
amplified before cycle 35. ARN concentration was determined 
spectrophotometrically and the quality of the samples was checked in agarose 
gels in denatured conditions. Quantification of specific genes was performed by 
qPCR in a two-step reverse transcription and real-time PCR using the iScript 
cDNA synthesis kit and iQ SYBR Green supermix (Bio-Rad). The rpsL gene 
was used as an internal reference to normalize the relative amount of RNA. The 
experiment was repeated in triplicate, using independent RNA extractions in 
every assay. The expression of the indicated genes was compared to their 
expression in the PAO1 strain. The genes were considered to be 
overexpressed when the amount of RNA was at least 4 times higher than that in 
PAO1.  
In the same set of 8 strains, the sequences of the regulatory genes mexR, 
mexZ, nfxB, nalC and nalD were determined after their amplification by PCR, 
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using the primers indicated in table 2. Amplicons were sequenced, and the 
BLAST program was used to compare the nucleotide and protein sequences to 
those available on the www.ncbi.nlm.nih.gov website. 
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RESULTS AND DISCUSSION.  
Reference microdilution confirmed that the MICs of cefepime were ≥3, 2 and 1 
twofold dilutions higher than that of ceftazidime for 10 (9.5%), 35 (33.3%) and 
23 (22%) of the corresponding isolates. However, in 37 (35.2%) isolates the 
MICs of cefepime were the same or 1 dilution lower that those of ceftazidime. 
Interestingly, differences in MIC of cefepime by the reference and the 
commercial method did not translate into either very major (false susceptibility) 
or major (false resistance) errors, but in 5 (4.8%) isolates caused a minor error 
(intermediate by reference microdilution and resistance by the automatic 
system). The same clinical categories were obtained with microdilution and with 
the standardized disk diffusion method, except for one isolate susceptible to 
cefepime by microdilution and resistant by disk-diffusion and two other isolates 
susceptible to cefepime by microdilution and intermediate by disk-diffusion. 
These results support that identification of P. aeruginosa strains more resistant 
to cefepime than to ceftazidime with the MicroScan WalkAway system is not 
completely reliable. This agrees with multiple reports [12-17] indicating the 
difficulties of automatic systems when testing cefepime against P. aeruginosa.  
There is scarce information on the clinical aspects related to P. aeruginosa less 
susceptible to cefepime than to ceftazidime. Our isolates were obtained from a 
variety of clinical samples, as already documented in another study [7].  The 
use of piperacillin-tazobactam has been reported as an independent risk factor 
for the acquisition of P. aeruginosa with this phenotype [7]. It is possible that the 
use of quinolones, which are good substrates for different efflux pumps [8],  
may also select for strains with this phenotype.  
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The combined typing strategy of Rep-PCR/PFGE allowed the identification of 
47 different clones, and organisms of the same clone presented  similar (±1 
twofold dilution) MICs of cefepime and ceftazidime. This polyclonal situation 
contrast with the results from another study in Spain, documenting the 
expansion of a single clone affecting 51 patients [7].  
Oxacillinase genes were not detected, while the blaPSE-1 gene was amplified 
in 9 (13.2%) isolates. This indicates that the polyclonal nature of our isolates is 
not due to horizontal transmission of the genes encoding PSE-1 or an 
oxacillinase. The possible contribution of AmpC hyperexpression in our isolates 
was ruled out testing (by disk-diffusion) both ceftazidime and cefepime in media 
with or without cloxacillin (Sigma, 250 mg/l). The inhibition zones of cefazidime 
did not change (>=5 mm)  in  the presence of cloxacillin for any of the strains, 
while a change was observed for cefepime in  only three strains (none of which 
were any of the 8 isolates studied in detail). 
The 8 isolates studied in detail, overexpressed mexY. However, there was not a 
clear relationship between the level of mexY expression and the MIC of 
cefepime. Only 3 strains showed significant levels of expression of mexD with 
MIC values of ceftazidime/cefepime ranging from 2-8/4-16 µg/ml (Table 1); 
These strains lack PSE-1 but as they also displayed increased expression of 
mexY, it is rather difficult to define the actual contribution of either (or even 
both) efflux systems in the observed phenotypes. These three isolates 
overexpressing both mexY and mexD had different MIC values of cefepime and 
were not the ones with the highest MICs of cefepime suggesting that in addition 
of the (plausible) role of MexXY-OprM and perhaps that of MexCD-OprJ, other 
factors should be related in the strains we studied. mexB was also 
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overexpressed in 2 strains, but this overexpression is likely unrelated to the 
studied phenotype (Table 1). 
Among the 8 strains studied in detail, HUMV_038 and HUMV_110 expressed 
PSE-1, but it is difficult to demonstrate whether their susceptibilities to 
ceftazidime and cefepime are due to MexXY efflux activity or PSE-1 expression. 
Several mutations at DNA and protein levels were observed in all the efflux 
systems regulators we studied. In MexR, the Val-126Glu substitution was found 
in 7 out of the 8 strains (Table 1). This previously described mutation [23-25] 
was considered non significant as it was also observed in susceptible wild-type 
strains. Strain HUMV_026 carried a Thr-130Pro substitution. A similar amino 
acid substitution at the same position (Thr-130Ser) was described before [25] 
with no significant differences between susceptible and resistant isolates. A 
frameshift mutation due to an insertion of 12 bp between nucleotides 400 and 
401 was also discovered in strain HUMV_026. This mutation affects the C-
terminal portion of the protein including the stop codon TAA found in PAO1, 
resulting in a larger peptide. Frameshit mutations in MexR have already been 
reported related to MexAB-OprM overexpression [23, 26, 27]. Nevertheless, this 
change does not seem to considerably affect the ability of MexR to bind the 
promoter region of mexAB-oprM nor the way the repressor protein modulates 
the expression of this operon, as no high levels of expression were registered 
for mexB in strain HUMV_026. 
NalC, the repressor of ArmR (antirepressor for MexR) displayed 3 recurrent 
amino acid substitutions: Gly-71Glu, Glu-153Gln and Ser-209Arg. Such 
mutations have also been described [26] and they seemed not to affect the 
integrity of NalC. Three new amino acid substitutions were observed in NalC: 
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Ala-145Val, Pro-210Lys, Ala-186Thr, but we could not associate them with 
changes in expression of mexB. In strain HUMV_038, nalC shows two 
nucleotide deletions at positions 123 and 147 generating a frameshift affecting 
the N-terminal portion of the protein, which contains the DNA binding domain 
(from residues 20-64). The new protein has 149 amino acids residues instead of 
the 213 of the PAO1 strain. A 1-bp insertion in the nalC gene of strain 
HUMV_026 at position 611 generates a frameshift mutation that affects the C-
terminal extreme of the protein from residue Lys-203. Strain HUMV_039 has 1 
nucleotide deletion in nalC at position 586 creating a frameshift that affects its 
C-terminal portion of the protein from residue Ser195. It is difficult to correlate 
the effects of the single base changes in nalC of HUMV_026 and HUMV_039 
with changes in expression of MexB. In strain HUMV_110 the combination of 
mutation in both proteins (MexR: Val-126Glu; NalC: Gly-71Glu, Glu-153Gln and 
Ser-209Arg) may be related to the increased levels of MexB expression.  
Mutations in nalD were only observed in strain HUMV_038, which displayed a 
16 bp deletion at nucleotide 85 and a 3 bp deletion at position 101. Both 
deletions affect the N-terminal portion of the protein that contains the DNA 
binding domain, generating a truncated peptide. These changes together with 
those found in NalC may be responsible for MexB overexpression in this strain.  
A previous study also showed that combined action of mutations in mexR, nalC 
and nalD may be responsible for the overexpression of MexAB-OprM [25]. 
mexZ presented several mutations in 5 out of 8 strains. Several attempts to 
amplify mexZ in strain HUMV_026 were unsuccessful, suggesting that this 
strain lacks this gene, possibly due to a deletion. This can also explain the 
overexpression of MexY. Two isolates (HUMV_038 and HUMV_110 ) had a 
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substitution of 1 nucleotide at position 60 (GAG for TAG), which generates a 
premature stop codon resulting in a truncated peptide, lacking the first 28 
residues where a fragment of the DNA binding domain (from residues 15-60) is 
present in wild-type strains. This mutation could correlate with MexY 
overexpression (Table 1). The mexZ gene of strain HUMV_039 has an insertion 
of 71 bp between nucleotides 321 and 322. This sequence is almost identical 
(only differs in 1 bp) to a sequence placed immediately upstream, flanked by 
two imperfect direct repeats of 12 bp G(C)GGT(C)GCTGGACA that most likely 
caused such sequence duplication. This mutation could also explain the high 
levels of expression of mexY (93.3-fold higher) when compared to that of PAO1 
(Table 1). The strain HUMV_072 presented an insertion of 1 bp in mexZ 
between nucleotides at positions 591 and 592. This insertion leads to a 
frameshift that affects the C-terminal extreme of MexZ from Asp-297 and may 
explain the high levels of expression of mexY and consequently the MIC values 
of cefepime (16 µg/ml) observed in this strain (Table 1). The Gly-195Arg 
substitution is similar to a formerly described (Gly-195Glu) that correlated with 
overexpression of mexY and high MIC values of FEP in clinical strains of P. 
aeruginosa [2]. Other mutations observed in MexZ were single amino acid 
substitutions: Leu-162Arg (strain HUMV_039), and Gly-137Asp plus Gly-195Arg 
(strain HUMV_111). The mexZ gene of strains HUMV_089 and HUMV_057 did 
not show any mutations, however mexY was overexpressed in both strains 
(Table 1), which may be due to mutations in additional mediators that control 
the expression of mexXY, as previously suggested in other studies  [26, 28, 29].  
Several different amino acid substitutions in NfxB, the repressor of MexCD-
OprJ, have been identified.  The amino acid substitutions Arg-33His and Asp-
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68Gly were previously described in clinical strains of P. aeruginosa [25, 30] but 
with different residue numbers (Arg-21His and Asp-56Gly, respectively). This is 
probably due to a miss-annotation of nfxB, hence the differences in the residues 
positions reported. In this study we have assumed that the start codon of the 
nfxB gene might be 36 nts upstream the “proposed” ATG, considering that the 
sequence AGGCCAG within the bounds of the gene (12 bp upstream the ATG) 
is more likely to be a ribosome binding site of this gene. In addition, the size of 
this “corrected sequence” is similar to that of its homolog genes in other P. 
aeruginosa strains like PA7 or even to that of other pseudomonads like P. 
syringae B728a. These two amino acid substitutions (Arg-21His and Asp-56Gly) 
were found to be related to ciprofloxacin resistance [30]. In the strain 
HUMV_057 a deletion of 1 bp in nfxB at position 541 leads to a frameshift 
mutation affecting the C-terminal portion of NfxB from residue N180. Beside this 
there is a single base pair substitution at position 600, affecting the stop codon 
(TGA for TGG), which translates in a protein larger than the one in the wild type 
PAO1. Interestingly, mutations in the stop codon, leading to a longer predicted 
NfxB, have also been documented among M xCD-OprJ hyperproducing 
mutants in vitro and in animal models of infection [31]. 
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Table 1. MICs of ceftazidime and cefepime against clinical strains of 
Pseudomonas aeruginosa and expression of efflux pump genes and amino acid 
variations in regulatory proteins of the corresponding organisms. 
 MIC (µg/ml) Efflux pumps 
expression 
Amino acid substitutions/mutations in 
regulatory proteins 
Strain CAZ FEP mexB mexD mexY 
bla
 
PSE-
1 MexZ NalD MexR NfxB NalC 
 
HUMV_
038 
 
 
2 
 
 
4 
 
5.64 
 
1 
 
95.3 
 
+ 
 
nt 60T-G 
 
nt 
85∆16 
nt 
101∆3 
 
 
V126E 
 
R5G 
K144I 
G71E 
E153Q 
nt 123∆1 
nt t147∆1 
 
HUMV_
039 
 
2 
 
4 
 
1.08 
 
 
18.1 
 
93.3 - 
L162R 
nt 
32171nt322 
 
wild-
type 
 
V126E 
R33H 
D68G 
G71E 
A145V 
nt 586∆1 
HUMV_
089 4 8 0.96 2 54.9 - wild-type 
wild-
type V126E w.t G71E 
 
HUMV_
026 
 
8 
 
16 
 
2.09 
 
4 
 
26.8 
 
- 
 
Not 
amplified 
 
wild-
type 
V126E 
T130P 
nt 
40012n
t 401 
R33H 
D68G 
K144
R 
N195I 
G71E 
A145V 
nt 6111nt 612 
 
HUMV_
110 
 
8 
 
16 
 
5.41 
 
2.4 
 
186.8 
 
+ 
 
nt 60T-G 
 
wild-
type 
 
V126E 
 
R5G 
G71E 
E153Q 
S209R 
 
HUMV_
057 
 
4 
 
16 
 
0.81 
 
150.5 
 
18.3 
 
- 
 
wild-type 
 
wild-
type 
 
w.t 
R54C 
nt 
541∆1 
nt 
600A-
G 
G71E 
S209R 
P210L 
HUMV_
111 16 64 1.1 1.7 152.7 - 
G137D 
G195R 
wild-
type V126E w.t G71E 
HUMV_
072 1 16 1.0 2.2 140 - 
nt 5911nt 
592 
wild-
type V126E T7N 
G71E 
A186T 
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Table 2.  Primers for amplification and expected amplicon sizes of genes 
involved in efflux systems regulation.  
Efflux system Gene Primers Sequence (5´-3´) Expected size (pb) 
NfxB_F AAATGATCTTTTGACAGCTAATTCCT MexCD-OprJ nfxB 
NfxB_R ACTGATCTTCCCGAGTGTCG 
760 
MexR_F TGTTCTTAAATATCCTCAAGCGG 
mexR 
MexR_R GTTGCATAGCGTTGTCCTCA 729 
NalC_F TCAACCCTAACGAGAAACGCT 
nalC 
NalC_R TCCACCTCACCGAACTGC 813 
NalD_F GCGGCTAAAATCGGTACACT 
MexAB-OprM 
nalD 
NalD_R ACGTCCAGGTGGATCTTGG 788 
MexZB_F CCCTTGTGAGGACGTTCA MexXY-OprM mexZ 
MexZB_R CCCAGAGCGATTGCAGATA 968 
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